Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology

Protecting the Heart: Treatment and Management

At a Glance

Naxos disease treatment focuses on controlling dangerous rhythms, limiting intense exercise, and supporting weakened heart function. Medicines, implanted defibrillators, rhythm procedures, and rare heart transplants are tailored to individual risk; they do not reverse the structural heart changes.

Managing the heart-related aspects of Naxos disease requires a proactive and highly personalized approach. Because Naxos disease involves Arrhythmogenic Cardiomyopathy (ACM), your care team will use established ACM treatment guidelines to manage heart rhythms and support heart function [1][2].

The primary goals of treatment are to manage symptoms, prevent dangerous heart rhythms, and treat any signs of heart failure. There is currently no established medication that reverses the underlying structural progression caused by the JUP mutation [3].

Medical Therapy: Beta-Blockers and Antiarrhythmics

Beta-blockers (such as carvedilol, metoprolol, or nadolol) are often prescribed as a foundational therapy [4]. However, they are not universally required for every asymptomatic person. They are typically used for:

  • Documented Arrhythmias: To help shield the heart from adrenaline, which is a known trigger for dangerous rhythms [4][5].
  • Symptomatic Ectopy: To reduce the frequency of uncomfortable “skipped beats.”
  • Heart Dysfunction: To support the heart if its pumping ability is weakened [6].

If beta-blockers alone are not enough to control dangerous or highly symptomatic arrhythmias, a specialist may add antiarrhythmic drugs like sotalol, amiodarone, or flecainide [4][7]. These are specialist options that carry risks of pro-arrhythmia and organ toxicity, requiring careful ongoing monitoring.

Protecting the Heart: The Role of ICDs

An Implantable Cardioverter-Defibrillator (ICD) is a small device placed under the skin that monitors the heart rhythm 24/7. If it detects a life-threatening rhythm, it can deliver an electrical shock to reset the heart [8].

  • Secondary Prevention: An ICD is strongly recommended for anyone who has already survived a cardiac arrest or experienced sustained ventricular tachycardia [4].
  • Primary Prevention: For those who have not had a major event, deciding on an ICD is a complex, shared decision-making process with an electrophysiologist (a heart rhythm specialist). While risk calculators evaluate factors like fainting (syncope), MRI scar tissue, and rhythm monitor results, they are not fully validated for all pediatric patients or all Naxos genotypes [9][10]. Your doctor will weigh the lifesaving benefits against the lifelong risks of lead failure, infection, and inappropriate shocks.

Catheter Ablation

If a patient has an ICD but continues to experience recurrent, sustained ventricular tachycardia despite medications, a procedure called catheter ablation may be considered [4]. During this procedure, an electrophysiologist uses a thin tube to neutralize the specific area of scar tissue causing the “short circuit” [11]. While ablation can significantly reduce the arrhythmia burden, it does not cure the underlying disease and does not replace the need for an ICD [12].

Exercise Restriction: A Critical Component

One of the most important aspects of managing Naxos disease is exercise restriction. High-intensity and endurance exercise (like competitive sports or long-distance running) puts immense mechanical strain on the heart, which can trigger life-threatening arrhythmias and accelerate the replacement of heart muscle with scar tissue [13][14].

Current guidelines strongly advise avoiding competitive and high-endurance sports for individuals with confirmed disease or biallelic mutations (two mutated copies) [5]. A cardiologist must prescribe an individualized activity plan, outlining what recreational or moderate activities are safe. Note that carriers (individuals with only one mutated copy) do not automatically face the same severe restrictions [15][16].

Advanced Care and Heart Failure

If the heart muscle weakens over time, leading to heart failure, doctors use contemporary guideline-directed medical therapy. Medications like diuretics (to remove excess fluid) or ACE inhibitors manage symptoms and support the heart’s workload [3][17]. While these therapies are highly effective for managing symptoms, they do not reverse the underlying JUP-related disease. In exceedingly rare, advanced cases where the heart function declines significantly despite maximum therapy, advanced options like a heart transplant may be considered [18][19].

Common questions in this guide

What medicines are used to treat Naxos disease?
Doctors may use beta-blockers such as carvedilol, metoprolol, or nadolol to control abnormal rhythms, reduce uncomfortable skipped beats, or support a weakened heart. If these medicines are not enough, a heart-rhythm specialist may consider sotalol, amiodarone, or flecainide with careful monitoring. These medicines manage the heart effects but do not reverse the underlying structural changes.
When might someone with Naxos disease need an ICD?
An implantable cardioverter-defibrillator (ICD) is strongly recommended for people who have survived cardiac arrest or had sustained ventricular tachycardia, a dangerous fast rhythm from the lower heart chambers. For people who have not had one of these events, the decision may depend on fainting, scar tissue seen on heart MRI, and rhythm-monitor results. An electrophysiologist weighs the possible protection against infection, lead problems, and inappropriate shocks.
What exercise is safe with Naxos disease?
People with confirmed Naxos disease or two altered copies of the gene are generally advised to avoid competitive and high-endurance sports, such as long-distance running. A cardiologist should create an individualized plan for recreational or moderate activity. People with only one altered copy are not automatically subject to the same restrictions, but they should still discuss activity with their doctor.
Can catheter ablation cure Naxos disease or replace an ICD?
Catheter ablation can reduce recurrent sustained ventricular tachycardia when medicines are not enough by treating the scar area that triggers the abnormal rhythm. It does not cure the underlying disease. It also does not replace an ICD when an ICD is needed for protection from life-threatening rhythms.
How is heart failure treated in Naxos disease?
If Naxos disease weakens the heart, doctors may use medicines such as diuretics to remove extra fluid and ACE inhibitors to reduce the heart’s workload. These treatments can relieve symptoms and support heart function but do not reverse the JUP-related disease. In rare advanced cases despite maximum treatment, a heart transplant may be considered.

Get notified when new evidence is published on Naxos disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Naxos disease - a narrative review.

    Leopoulou M, Mattsson G, LeQuang JA, et al.

    Expert review of cardiovascular therapy 2020; (18(11)):801-808 doi:10.1080/14779072.2020.1828064.

    PMID: 32966140
  2. 2

    Cardiocutaneous syndrome (Naxos disease) in a Bangladeshi boy.

    Islam AM, Rahman MT, Chowdhury AH

    Cardiovascular diagnosis and therapy 2016; (6(5)):462-465 doi:10.21037/cdt.2016.03.07.

    PMID: 27747171
  3. 3

    Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

    Akdis D, Brunckhorst C, Duru F, Saguner AM

    Arrhythmia & electrophysiology review 2016; (5(2)):90-101 doi:10.15420/AER.2016.4.3.

    PMID: 27617087
  4. 4

    Arrhythmogenic Right Ventricular Cardiomyopathy: Diagnosis, Risk Stratification, and Treatment.

    Kreimer F, Saguner AM, Akin I, et al.

    Deutsches Arzteblatt international 2025; (122(9)):229-234.

    PMID: 40202346
  5. 5

    Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity.

    Te Riele ASJM, James CA, Calkins H, Tsatsopoulou A

    Frontiers in pediatrics 2021; (9()):750916 doi:10.3389/fped.2021.750916.

    PMID: 34926342
  6. 6

    Antiarrhythmic therapy and risk of cumulative ventricular arrhythmias in arrhythmogenic right ventricle cardiomyopathy.

    Cappelletto C, Gregorio C, Barbati G, et al.

    International journal of cardiology 2021; (334()):58-64 doi:10.1016/j.ijcard.2021.04.069.

    PMID: 33961942
  7. 7

    Antiarrhythmic Drug Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy.

    Gaine SP, Calkins H

    Biomedicines 2023; (11(4)) doi:10.3390/biomedicines11041213.

    PMID: 37189831
  8. 8

    Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy.

    Zorzi A, Rigato I, Bauce B, et al.

    Current cardiology reports 2016; (18(6)):57 doi:10.1007/s11886-016-0734-9.

    PMID: 27147509
  9. 9

    [Arrhythmogenic right ventricular cardiomyopathy : An update].

    Marchetti M, Pascale P, Muller O, Lu H

    Annales de cardiologie et d'angeiologie 2022; (71(4)):223-227 doi:10.1016/j.ancard.2022.08.006.

    PMID: 36089416
  10. 10

    A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.

    Cadrin-Tourigny J, Bosman LP, Nozza A, et al.

    European heart journal 2022; (43(32)):e1-e9 doi:10.1093/eurheartj/ehac180.

    PMID: 35441664
  11. 11

    Clinical outcomes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy: Insights from the Johns Hopkins ARVC Program.

    Daimee UA, Assis FR, Murray B, et al.

    Heart rhythm 2021; (18(8)):1369-1376 doi:10.1016/j.hrthm.2021.04.028.

    PMID: 33933674
  12. 12

    Radiofrequency Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).

    Romero J, Grushko M, Briceño DF, et al.

    Current cardiology reports 2017; (19(9)):82 doi:10.1007/s11886-017-0893-3.

    PMID: 28779285
  13. 13

    Impact of dynamic physical exercise on high-risk definite arrhythmogenic right ventricular cardiomyopathy.

    Ruiz Salas A, Barrera Cordero A, Navarro-Arce I, et al.

    Journal of cardiovascular electrophysiology 2018; (29(11)):1523-1529 doi:10.1111/jce.13704.

    PMID: 30080280
  14. 14

    Arrhythmogenic right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry.

    Gasperetti A, James CA, Cerrone M, et al.

    European heart journal 2021; (42(13)):1231-1243 doi:10.1093/eurheartj/ehaa821.

    PMID: 33200174
  15. 15

    Running the Risk: Exercise and Arrhythmogenic Cardiomyopathy.

    Eberly L, Garg L, Vidula M, et al.

    Current treatment options in cardiovascular medicine 2021; (23(10)) doi:10.1007/s11936-021-00943-0.

    PMID: 35082480
  16. 16

    Role of Exercise as a Modulating Factor in Arrhythmogenic Cardiomyopathy.

    Zorzi A, Cipriani A, Bariani R, et al.

    Current cardiology reports 2021; (23(6)):57 doi:10.1007/s11886-021-01489-0.

    PMID: 33961139
  17. 17

    Effect of preload reducing therapy on right ventricular size and function in patients with arrhythmogenic right ventricular cardiomyopathy.

    Kalantarian S, Vittinghoff E, Klein L, Scheinman MM

    Heart rhythm 2021; (18(7)):1186-1191 doi:10.1016/j.hrthm.2021.03.018.

    PMID: 33722762
  18. 18

    Clinical course of arrhythmogenic right ventricular cardiomyopathy with end-stage heart failure and outcome after heart transplantation.

    Petruescu L, Lebreton G, Coutance G, et al.

    Archives of cardiovascular diseases 2023; (116(1)):9-17 doi:10.1016/j.acvd.2022.10.005.

    PMID: 36609000
  19. 19

    Heart transplantation in arrhythmogenic right ventricular cardiomyopathy - Experience from the Nordic ARVC Registry.

    Gilljam T, Haugaa KH, Jensen HK, et al.

    International journal of cardiology 2018; (250()):201-206 doi:10.1016/j.ijcard.2017.10.076.

    PMID: 29107359

This page is for informational purposes only and does not constitute medical advice. Your cardiology and electrophysiology team should tailor medicines, activity limits, ICD decisions, and other care to your specific situation.